Navigation Links
ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)

EXTON, Pa., March 29, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 clinical study to evaluate the safety and efficacy of C1 Esterase Inhibitor [Human] for the treatment of acute antibody-mediated rejection (AMR) in recipients of donor-specific cross-match positive kidney transplants.

This randomized, double blind, placebo-controlled study will evaluate the safety, tolerability and clinical effect of C1 Esterase Inhibitor [Human] for the treatment of acute antibody-mediated rejection in recipients of donor-specific cross-match positive kidney transplants. The study will enroll 20 subjects (10 study drug/10 placebo), and will be conducted at up to four (4) transplant centers in the United States.  Subjects will be assessed after two weeks of treatment for safety, PK/PD, and clinical effect and again at six months post-transplant for graft function and patient survival.  

"Each year, thousands of kidney failure patients fail to receive a potentially life-saving transplant because of pre-existing antibodies to a prospective donor kidney," commented Marc E. Uknis, M.D., ViroPharma's medical director.  "These antibodies initiate complement-mediated inflammation and damage, better known as antibody mediated rejection, or AMR.  These patients, many of whom have a willing but incompatible live donor, are currently added to the deceased donor wait list and many will die waiting for a transplant. Current clinical therapies deal with removing antibodies from the circulation, but do not address the damage to the transplant caused by complement activation.  We have the potential with C1 esterase inhibitor - a complement inhibitor - to add to the treatment paradigms which could then permit broader access to transplantation for patients with such antibodies."

ViroPharma's C1 esterase inhibitor, commercially known as Cinryze® (C1 Esterase Inhibitor [Human]), is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease.

About Antibody Mediated Rejection

Antibody-mediated rejection is a type of organ transplant rejection that occurs when a patient has antibodies circulating in their blood against the donor organ (i.e. donor specific antibodies, or DSA).  These antibodies can activate the body's own defense mechanism, known as the complement cascade, which in turn causes a complement-mediated destruction of the transplanted organ.  Since there is no approved treatment for AMR, many thousands of renal failure patients that have DSA cannot be transplanted.  Furthermore, over time, all transplant patients can develop DSA and could lose their transplant to a chronic version of antibody/complement-mediated rejection of the transplanted organ.

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by the U.S. FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  C1 inhibitor therapy has been used acutely for more than 35 years in Europe to treat patients with C1 inhibitor deficiency. In the E.U., on March 17, 2011., the CHMP adopted a positive opinion for Cinryze for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment. The CHMP positive opinion forms the scientific basis for the European Commission to issue a binding decision for a Centralized Marketing Authorization, which is expected in the second quarter of 2011.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials.

Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile infection.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events, including the therapeutic indication and use, safety, efficacy, tolerability and potential of our C1 esterase inhibitor and our focus, goals, strategy, research and development programs, and ability to develop pharmaceutical products, commercialize pharmaceutical products, and execute on our plans, including clinical development activities with C1 esterase inhibitor related to the treatment of acute antibody-mediated rejection. This is the first study of our C1 esterase inhibitor in the treatment of acute antibody-mediated rejection. There can be no assurance that that our phase 2 clinical program with C1 esterase inhibitor will yield positive results or support further development of C1 esterase inhibitor for treatment of acute antibody-mediated rejection. The FDA or EMA may view the data regarding utilization of C1 esterase inhibitor as treatment of acute antibody-mediated rejection as insufficient or inconclusive, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, or deny the approval of C1 esterase inhibitor for treatment of acute antibody-mediated rejection. These factors, and other factors, including, but not limited to those described in our annual report on Form 10-K for the year ended December 31, 2010 as filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
2. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
3. ViroPharma Announces Securities Repurchase Program
4. ViroPharma to Participate in Two March Healthcare Conferences
5. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
6. ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
7. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
8. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
9. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
10. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
11. ViroPharma To Participate in Two September Healthcare Investor Conferences
Post Your Comments:
(Date:12/1/2015)... 1, 2015 A federal court has denied the ... a lawsuit filed by the Pharmaceutical Care Management Association (PCMA) ... a new law that forces employers and consumers to pay ... Arkansas must now defend a law that raises ... and CEO Mark Merritt . --> ...
(Date:12/1/2015)... 2015  Athletic apparel company Tommie Copper ... pay $1.35 million to settle Federal Trade Commission ... compression clothing would relieve severe and chronic pain ... Tommie Copper,s proposed settlement ... its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... , Dec. 1, 2015 Assurex ... its GeneSight® Psychotropic test giving healthcare providers an expanded ... decisions for patients suffering from depression, anxiety, bipolar ... behavioral health conditions. i . ... --> With the addition of two new ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of ... latest addition to the devices for sale in the United States. Clarity is ... long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to own ...
(Date:12/1/2015)... ... 01, 2015 , ... PYA’s latest white paper, “ PYA ... main “pain point” for merging or aligning healthcare provider organizations—when mergers and other ... This quick-read guidance suggests that failing to recognize the power of an ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won a tender ... be from the China Disabled Persons’ Federation, a central government association, for nearly 2,000 ... and adults suffering from severe and profound hearing loss . The company holds ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Trust on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. ... the patient care experience, and propose exciting enhancements to the medical landscape. , ...
Breaking Medicine News(10 mins):